Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Thyroid Eye Disease pipeline constitutes key companies continuously working towards developing Thyroid Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Thyroid Eye Disease Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/thyroid-eye-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Thyroid Eye Disease Market.

The Thyroid Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Thyroid Eye Disease Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Thyroid Eye Disease treatment therapies with a considerable amount of success over the years.

*
Thyroid Eye Disease companies working in the treatment market are Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, ACELYRIN Inc., Horizon Therapeutics USA, Inc., Neothetics, Inc, Sling Therapeutics, Inc., Novartis, and others, are developing therapies for the Thyroid Eye Disease treatment

*
Emerging Thyroid Eye Disease therapies in the different phases of clinical trials are- Batoclimab (IMVT 1401), COSENTYX (secukinumab), VRDN-001, Linsitinib, Aflibercept, VB421, RVT-140, lonigutamab, Teprotumumab, LIPO-102, Linsitinib, CFZ533, and others are expected to have a significant impact on the Thyroid Eye Disease market in the coming years.

*
In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing oral small molecule therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from its Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company's lead candidate, is a twice-daily oral small molecule targeting the validated IGF-1R pathway. It has demonstrated a well-established safety profile, having been studied in over 900 patients across 15 clinical trials for various conditions.

*
In December 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to developing potential best-in-class treatments for serious and rare conditions, has announced encouraging topline results from its Phase 3 THRIVE-2 clinical trial of veligrotug (veli). This intravenously administered anti-IGF-1R antibody was evaluated in patients with chronic thyroid eye disease (TED), an autoimmune disorder marked by inflammation, tissue expansion, and damage around the eyes.

Thyroid Eye Disease Overview

Thyroid Eye Disease (TED), also known as Graves' orbitopathy or thyroid-associated ophthalmopathy, is an autoimmune condition where the immune system mistakenly attacks the tissues around the eyes. It is commonly associated with Graves' disease, a type of hyperthyroidism. TED causes inflammation and swelling of the eye muscles, eyelids, and surrounding tissues, leading to symptoms such as bulging eyes (proptosis), double vision, dry or irritated eyes, and, in severe cases, vision loss. The disease typically progresses through an active (inflammatory) phase and later stabilizes. Early diagnosis and management are crucial to prevent complications and preserve vision.

Get a Free Sample PDF Report to know more about Thyroid Eye Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/thyroid-eye-disease-pipeline-insight [https://www.delveinsight.com/report-store/thyroid-eye-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Thyroid Eye Disease Drugs Under Different Phases of Clinical Development Include:

*
Batoclimab (IMVT 1401): Immunovant Sciences

*
COSENTYX (secukinumab): Novartis

*
VRDN-001: Viridian Therapeutics

*
Linsitinib: Sling Therapeutics

*
Aflibercept: Regeneron Pharmaceuticals

*
VB421: ValenzaBio

*
Secukinumab: Novartis

*
RVT-1401: Immunovant Sciences GmbH

*
lonigutamab: ACELYRIN Inc.

*
Teprotumumab: Horizon Therapeutics USA, Inc.

*
LIPO-102: Neothetics, Inc

*
Linsitinib: Sling Therapeutics, Inc.

*
CFZ533: Novartis

Thyroid Eye Disease Pipeline Therapeutics Assessment

*
Thyroid Eye Disease Assessment by Product Type

*
Thyroid Eye Disease By Stage and Product Type

*
Thyroid Eye Disease Assessment by Route of Administration

*
Thyroid Eye Disease By Stage and Route of Administration

*
Thyroid Eye Disease Assessment by Molecule Type

*
Thyroid Eye Disease by Stage and Molecule Type

DelveInsight's Thyroid Eye Disease Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Thyroid Eye Disease product details are provided in the report. Download the Thyroid Eye Disease pipeline report to learn more about the emerging Thyroid Eye Disease therapies [https://www.delveinsight.com/sample-request/thyroid-eye-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Thyroid Eye Disease Therapeutics Market include:

Key companies developing therapies for Thyroid Eye Disease are - Horizon Therapeutics PLC, Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc. (Johnson & Johnson Vision Care, Inc.), AbbVie Inc., Cipla Inc., Bausch & Lomb Incorporated, Sun Pharmaceutical Industries, Inc., Eyevance Pharmaceuticals LLC, Alcon Inc., and others.

Thyroid Eye Disease Pipeline Analysis:

The Thyroid Eye Disease pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Thyroid Eye Disease with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Thyroid Eye Disease Treatment.

*
Thyroid Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Thyroid Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Thyroid Eye Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Thyroid Eye Disease drugs and therapies [https://www.delveinsight.com/sample-request/thyroid-eye-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Thyroid Eye Disease Pipeline Market Drivers

*
Rising prevalence of Graves' disease and autoimmune thyroid disorders globally, Increased awareness and early diagnosis of Thyroid Eye Disease, Advancements in biologic therapies, such as Teprotumumab, improving patient outcomes, Ongoing clinical trials and strong pipeline of innovative TED therapies, Improved healthcare infrastructure and access to specialty care in emerging markets, Growing demand for targeted and personalized treatment options, High cost of biologic therapies, limiting patient accessibility, are some of the important factors that are fueling the Thyroid Eye Disease Market.

Thyroid Eye Disease Pipeline Market Barriers

*
However, Limited availability of FDA-approved treatments, especially outside the U.S, Delayed diagnosis and misdiagnosis, reducing timely intervention, Adverse effects and safety concerns associated with long-term immunosuppressive therapy, Lack of disease-specific awareness among primary care providers, and other factors are creating obstacles in the Thyroid Eye Disease Market growth.

Scope of Thyroid Eye Disease Pipeline Drug Insight

*
Coverage: Global

*
Key Thyroid Eye Disease Companies: Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, ACELYRIN Inc., Horizon Therapeutics USA, Inc., Neothetics, Inc, Sling Therapeutics, Inc., Novartis, and others

*
Key Thyroid Eye Disease Therapies: Batoclimab (IMVT 1401), COSENTYX (secukinumab), VRDN-001, Linsitinib, Aflibercept, VB421, RVT-140, lonigutamab, Teprotumumab, LIPO-102, Linsitinib, CFZ533, and others

*
Thyroid Eye Disease Therapeutic Assessment: Thyroid Eye Disease current marketed and Thyroid Eye Disease emerging therapies

*
Thyroid Eye Disease Market Dynamics: Thyroid Eye Disease market drivers and Thyroid Eye Disease market barriers

Request for Sample PDF Report for Thyroid Eye Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/thyroid-eye-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Thyroid Eye Disease Report Introduction

2. Thyroid Eye Disease Executive Summary

3. Thyroid Eye Disease Overview

4. Thyroid Eye Disease- Analytical Perspective In-depth Commercial Assessment

5. Thyroid Eye Disease Pipeline Therapeutics

6. Thyroid Eye Disease Late Stage Products (Phase II/III)

7. Thyroid Eye Disease Mid Stage Products (Phase II)

8. Thyroid Eye Disease Early Stage Products (Phase I)

9. Thyroid Eye Disease Preclinical Stage Products

10. Thyroid Eye Disease Therapeutics Assessment

11. Thyroid Eye Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Thyroid Eye Disease Key Companies

14. Thyroid Eye Disease Key Products

15. Thyroid Eye Disease Unmet Needs

16 . Thyroid Eye Disease Market Drivers and Barriers

17. Thyroid Eye Disease Future Perspectives and Conclusion

18. Thyroid Eye Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=thyroid-eye-disease-pipeline-2025-moa-roa-and-clinical-trial-insights-explored-by-delveinsight-immunovant-sciences-novartis-viridian-therapeutics-sling-therapeutics-regeneron-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.